1. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? 
Pieter Sonneveld, Edwin De Wit, Philippe Moreau 
Critical Reviews in Oncology / Hematology 
Volume 112, Pages (April 2017)
DOI: /j.critrevonc
Copyright © 2017 Amgen Inc. Terms and Conditions

2. Fig. 1
Evolving treatment strategies for patients with relapsed and/or refractory multiple myeloma.
Figure shows the publication of key clinical trials and European approval of agents for the treatment of relapsed and/or refractory multiple myeloma. aApproved for use only as first-line therapy for multiple myeloma. BCL-2i, B-cell lymphoma 2 inhibitor, BEND, bendamustine; BORT, bortezomib; CARF, carfilzomib; CDKi, cyclin-dependent kinase inhibitor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; HDAC, histone deacetylase; ISA, isatuximab; IXA, ixazomib; KSP-i, kinesin spindle protein inhibitor; LEN, lenalidomide; MARI, marizomib; OPRO, oprozomib; PAN, panobinostat; PD-1, programmed death protein 1; PD-L1, programmed death ligand 1; PIMKi, Pim kinase inhibitor; POM, pomalidomide; RICO, ricolinostat; ROM, romidepsin; SINE, selective inhibitor of nuclear export; THAL, thalidomide; VOR, vorinostat.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Amgen Inc. Terms and Conditions

3. Fig. 2
Overall response rates in key phase 3 studies in patients with relapsed and/or refractory multiple myeloma.
—Approved for use in the USA and in Europe in patients with relapsed and/or refractory multiple myeloma Approved for use in the USA in patients with relapsed and/or refractory multiple myeloma. aCR not available (ORR: sCR+CR+VGPR+PR); bCR+near CR; cNot yet approved for use in patients with RRMM; dsCR+CR. BORT, bortezomib; CARF, carfilzomib; CR, complete response; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; IMiD, immunomodulatory drug; LEN, lenalidomide; ORR, overall response rate; PAN, panobinostat; PI, proteasome inhibitor; PLD, pegylated liposomal doxorubicin; POM, pomalidomide; PR, partial response; sCR, stringent complete response; THAL, thalidomide; VGPR, very good partial response; VOR, vorinostat.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2017 Amgen Inc. Terms and Conditions